Biosergen publishes interim report for third quarter 2022 - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Biosergen publishes interim report for third quarter 2022

Wednesday, November 30, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net

Summary of the Interim Report for Q3 2022

2022 2021 2022 2021 2021
TSEK July-Sep July-Sep Jan-Sep Jan-Sep Jan-Dec
Other income 493 2.652 3.219 4.653 8.573
Profit/loss before depreciation (EBITDA) -14.515 -6.404 -27.496 -24.202 -34.077
Operating profit/loss befor net financials -14.515 -6.404 -27.496 -24.202 -34.077
Netprofit/loss for the period -14.499 -6.550 -27.474 -24.359 -34.318
Earnings per share (SEK) -0,51 -0,40 -0,97 -1,51 -1,22

Highlights during Q3 2022

  • August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
  • August 31, Biosergen receives a loan of SEK 7 million to finance continued development
  • September 2, Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
  • September 8, Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study

Highlights after the period

  • October 4, Biosergen announces the outcome in the rights issue

The Financial report can be found on our website: https://biosergen.net/investors/filings

Bifogade filer

Nyheter om Biosergen

Läses av andra just nu

Om aktien Biosergen

Senaste nytt